;PMID: 9159349
;source_file_766.mrg
;Release 0.9 of PennBioIE
;Funded by NSF ITR EIA-0205448

;0)section:[e:0..35] = [t:0..35]
;1)sentence:[e:40..122] = [t:40..122]
;2)section:[e:126..188] = [t:126..188]
;3)section:[e:192..296] = [t:192..296]
;4)sentence:[e:300..310] = [t:300..310]
;5)sentence:[e:311..515] = [t:311..515]
;6)sentence:[e:516..638] = [t:516..638]
;7)sentence:[e:639..900] = [t:639..900]
;8)sentence:[e:901..909] = [t:901..909]
;9)sentence:[e:910..1087] = [t:910..1087]
;10)sentence:[e:1089..1163] = [t:1089..1163]
;11)sentence:[e:1164..1211] = [t:1164..1211]
;12)sentence:[e:1212..1491] = [t:1212..1491]
;13)sentence:[e:1492..1500] = [t:1492..1500]
;14)sentence:[e:1501..1553] = [t:1501..1553]
;15)sentence:[e:1554..1622] = [t:1554..1622]
;16)sentence:[e:1623..1767] = [t:1623..1767]
;17)sentence:[e:1768..1780] = [t:1768..1780]
;18)sentence:[e:1781..1875] = [t:1781..1875]
;19)sentence:[e:1877..1997] = [t:1877..1997]
;20)sentence:[e:1998..2152] = [t:1998..2152]
;21)section:[e:2156..2200] = [t:2156..2200]

;section 0 Span:0..35
;Gynecol Oncol  1997 May;65(2):343-7
(SEC
  (FRAG (RB:[0..7] Gynecol) (VB:[8..13] Oncol) (CD:[15..19] 1997)
        (CC:[20..27] May;65-LRB-) (CD:[27..28] 2) (-RRB-:[28..29] -RRB-)
        (CD:[29..33] :343) (::[33..34] -) (CD:[34..35] 7)))

;sentence 1 Span:40..122
;Identification of H, K, and N-ras point mutations in stage IB cervical 
;carcinoma.
;[58..59]...[69..73]:gene-rna:"H"..."-ras"
;[61..62]...[69..73]:gene-rna:"K"..."-ras"
;[68..73]:gene-rna:"N-ras"
;[74..89]:variation-type:"point mutations"
;[93..121]:malignancy:"stage IB cervical  carcinoma"
(SENT
  (NP-HLN
    (NP (NN:[40..54] Identification))
    (PP (IN:[55..57] of)
      (NP
        (NP
          (NML (NN:[58..59] H)
            (NML-2 (-NONE-:[59..59] *P*)))
          (NML-1 (-NONE-:[59..59] *P*)))
        (,:[59..60] ,)
        (NP
          (NML (NN:[61..62] K)
            (NML-2 (-NONE-:[62..62] *P*)))
          (NML-1 (-NONE-:[62..62] *P*)))
        (,:[62..63] ,) (CC:[64..67] and)
        (NP
          (NML (NN:[68..69] N) (HYPH:[69..70] -)
            (NML-2 (NN:[70..73] ras)))
          (NML-1 (NN:[74..79] point) (NNS:[80..89] mutations)))))
    (PP-LOC (IN:[90..92] in)
      (NP
        (NML (NN:[93..98] stage) (NN:[99..101] IB))
        (JJ:[102..110] cervical) (NN:[112..121] carcinoma)))
    (.:[121..122] .)))

;section 2 Span:126..188
;Grendys EC Jr, Barnes WA, Weitzel J, Sparkowski J, Schlegel R.
(SEC
  (FRAG (NNP:[126..133] Grendys) (NNP:[134..136] EC) (NNP:[137..139] Jr)
        (,:[139..140] ,) (NNP:[141..147] Barnes) (NNP:[148..150] WA)
        (,:[150..151] ,) (NNP:[152..159] Weitzel) (NNP:[160..162] J,)
        (NNP:[163..173] Sparkowski) (NNP:[174..176] J,)
        (NNP:[177..185] Schlegel) (NNP:[186..188] R.)))

;section 3 Span:192..296
;Division of Gynecologic Oncology, Moffitt Cancer Center, University of South 
;Florida, Tampa 33612, USA.
(SEC
  (FRAG (NNP:[192..200] Division) (IN:[201..203] of)
        (NNP:[204..215] Gynecologic) (NNP:[216..224] Oncology) (,:[224..225] ,)
        (NNP:[226..233] Moffitt) (NNP:[234..240] Cancer) (NNP:[241..247] Center)
        (,:[247..248] ,) (NNP:[249..259] University) (IN:[260..262] of)
        (NNP:[263..268] South) (NNP:[270..277] Florida) (,:[277..278] ,)
        (NNP:[279..284] Tampa) (VBD:[285..290] 33612) (NNP:[290..291] ,)
        (NNP:[292..295] USA) (.:[295..296] .)))

;sentence 4 Span:300..310
;OBJECTIVE:
(SENT
  (NP (NN:[300..309] OBJECTIVE) (::[309..310] :)))

;sentence 5 Span:311..515
;The ras oncogenes, Harvey (H), Kirsten (K), and neuroblastoma (N),  are a
;family of genes coding for a membrane-associated protein (p21) which 
;possesses inherent guanine triphosphatase (GTPase) activity.
;[315..318]:gene-rna:"ras"
;[330..336]:gene-rna:"Harvey"
;[338..339]:gene-rna:"H"
;[342..349]:gene-rna:"Kirsten"
;[351..352]:gene-rna:"K"
;[359..372]:gene-rna:"neuroblastoma"
;[374..375]:gene-rna:"N"
;[443..446]:gene-protein:"p21"
;[474..496]:gene-protein:"guanine triphosphatase"
;[498..504]:gene-protein:"GTPase"
(SENT
  (S
    (NP-SBJ
      (NP (DT:[311..314] The) (NN:[315..318] ras) (NNS:[319..328] oncogenes))
      (,:[328..329] ,)
      (NP
        (NP
          (NP (NNP:[330..336] Harvey))
          (NP (-LRB-:[337..338] -LRB-) (NN:[338..339] H)
              (-RRB-:[339..340] -RRB-)))
        (,:[340..341] ,)
        (NP
          (NP (NNP:[342..349] Kirsten))
          (NP (-LRB-:[350..351] -LRB-) (NN:[351..352] K)
              (-RRB-:[352..353] -RRB-)))
        (,:[353..354] ,) (CC:[355..358] and)
        (NP
          (NP (NN:[359..372] neuroblastoma))
          (NP (-LRB-:[373..374] -LRB-) (NN:[374..375] N)
              (-RRB-:[375..376] -RRB-)))))
    (,:[376..377] ,)
    (VP (VBP:[379..382] are)
      (NP-PRD
        (NP (DT:[383..384] a) (NN:[385..391] family))
        (PP (IN:[392..394] of)
          (NP
            (NP (NNS:[395..400] genes))
            (VP (VBG:[401..407] coding)
              (PP (IN:[408..411] for)
                (NP
                  (NP (DT:[412..413] a)
                    (ADJP (NN:[414..422] membrane) (HYPH:[422..423] -)
                          (VBN:[423..433] associated))
                    (NN:[434..441] protein)
                    (PRN (-LRB-:[442..443] -LRB-)
                      (NP (NN:[443..446] p21))
                      (-RRB-:[446..447] -RRB-)))
                  (SBAR
                    (WHNP-1 (WDT:[448..453] which))
                    (S
                      (NP-SBJ-1 (-NONE-:[453..453] *T*))
                      (VP (VBZ:[455..464] possesses)
                        (NP (JJ:[465..473] inherent)
                          (NML
                            (NML (NN:[474..481] guanine)
                                 (NN:[482..496] triphosphatase))
                            (NML (-LRB-:[497..498] -LRB-) (NN:[498..504] GTPase)
                                 (-RRB-:[504..505] -RRB-)))
                          (NN:[506..514] activity))))))))))))
    (.:[514..515] .)))

;sentence 6 Span:516..638
;Point mutagenesis  at codons 12, 13, and 61 has been implicated in ras
;activation and subsequent  cellular transformation.
;[538..547]:variation-location:"codons 12"
;[538..544]...[557..559]:variation-location:"codons"..."61"
;[538..544]...[549..551]:variation-location:"codons"..."13"
;[583..586]:gene-rna:"ras"
(SENT
  (S
    (NP-SBJ-2
      (NP (NN:[516..521] Point) (NN:[522..533] mutagenesis))
      (PP-LOC (IN:[535..537] at)
        (NP
          (NP
            (NML-1 (NNS:[538..544] codons))
            (CD:[545..547] 12))
          (,:[547..548] ,)
          (NP
            (NML-1 (-NONE-:[548..548] *P*))
            (CD:[549..551] 13))
          (,:[551..552] ,) (CC:[553..556] and)
          (NP
            (NML-1 (-NONE-:[556..556] *P*))
            (CD:[557..559] 61)))))
    (VP (VBZ:[560..563] has)
      (VP (VBN:[564..568] been)
        (VP (VBN:[569..579] implicated)
          (NP-2 (-NONE-:[579..579] *))
          (PP (IN:[580..582] in)
            (NP
              (NP (NN:[583..586] ras) (NN:[587..597] activation))
              (CC:[598..601] and)
              (NP (JJ:[602..612] subsequent) (JJ:[614..622] cellular)
                  (NN:[623..637] transformation)))))))
    (.:[637..638] .)))

;sentence 7 Span:639..900
;Given the epidemiologic relationship of HPV infection  with cervical
;carcinoma and the tumorigenic interaction of HPV and mutated ras  oncogenes,
;this study was undertaken to identify if mutated ras oncogenes were  present
;in early invasive cervical carcinomas.
;[699..717]:malignancy:"cervical carcinoma"
;[769..772]:gene-rna:"ras"
;[834..837]:gene-rna:"ras"
;[865..899]:malignancy:"early invasive cervical carcinomas"
(SENT
  (S
    (S-ADV
      (NP-SBJ-1 (-NONE-:[639..639] *))
      (VP (VBN:[639..644] Given)
        (NP-1 (-NONE-:[644..644] *))
        (NP
          (NP (DT:[645..648] the) (JJ:[649..662] epidemiologic)
              (NN:[663..675] relationship))
          (PP (IN:[676..678] of)
            (NP (NN:[679..682] HPV) (NN:[683..692] infection)))
          (PP (IN:[694..698] with)
            (NP
              (NP (JJ:[699..707] cervical) (NN:[708..717] carcinoma))
              (CC:[718..721] and)
              (NP
                (NP (DT:[722..725] the) (JJ:[726..737] tumorigenic)
                    (NN:[738..749] interaction))
                (PP (IN:[750..752] of)
                  (NP
                    (NP (NN:[753..756] HPV))
                    (CC:[757..760] and)
                    (NP (VBN:[761..768] mutated) (NN:[769..772] ras)
                        (NNS:[774..783] oncogenes))))))))))
    (,:[783..784] ,)
    (NP-SBJ-2 (DT:[785..789] this) (NN:[790..795] study))
    (VP (VBD:[796..799] was)
      (VP (VBN:[800..810] undertaken)
        (NP-2 (-NONE-:[810..810] *))
        (S-PRP
          (NP-SBJ (-NONE-:[810..810] *))
          (VP (TO:[811..813] to)
            (VP (VB:[814..822] identify)
              (SBAR-ADV (IN:[823..825] if)
                (S
                  (NP-SBJ (VBN:[826..833] mutated) (NN:[834..837] ras)
                          (NNS:[838..847] oncogenes))
                  (VP (VBD:[848..852] were)
                    (ADJP-PRD (JJ:[854..861] present)
                      (PP-LOC (IN:[862..864] in)
                        (NP (JJ:[865..870] early) (JJ:[871..879] invasive)
                            (JJ:[880..888] cervical) (NNS:[889..899] carcinomas))))))))))))
    (.:[899..900] .)))

;sentence 8 Span:901..909
;METHODS:
(SENT
  (NP (NNS:[901..908] METHODS) (::[908..909] :)))

;sentence 9 Span:910..1087
;A combination of  polymerase chain reaction (PCR) and dot-blot hybridization
;was used to determine  the frequency and types of ras point mutants occurring
;in cervical carcinoma.
;[928..938]:gene-protein:"polymerase"
;[1037..1040]:gene-rna:"ras"
;[1068..1086]:malignancy:"cervical carcinoma"
(SENT
  (S
    (NP-SBJ-1
      (NP (DT:[910..911] A) (NN:[912..923] combination))
      (PP (IN:[924..926] of)
        (NP
          (NP
            (NP (NN:[928..938] polymerase) (NN:[939..944] chain)
                (NN:[945..953] reaction))
            (NP (-LRB-:[954..955] -LRB-) (NN:[955..958] PCR)
                (-RRB-:[958..959] -RRB-)))
          (CC:[960..963] and)
          (NP
            (NML (NN:[964..967] dot) (HYPH:[967..968] -) (NN:[968..972] blot))
            (NN:[973..986] hybridization)))))
    (VP (VBD:[987..990] was)
      (VP (VBN:[991..995] used)
        (NP-1 (-NONE-:[995..995] *))
        (S-PRP
          (NP-SBJ (-NONE-:[995..995] *))
          (VP (TO:[996..998] to)
            (VP (VB:[999..1008] determine)
              (NP
                (NP
                  (NP (DT:[1010..1013] the) (NN:[1014..1023] frequency))
                  (CC:[1024..1027] and)
                  (NP (NNS:[1028..1033] types)))
                (PP (IN:[1034..1036] of)
                  (NP
                    (NP (NN:[1037..1040] ras) (NN:[1041..1046] point)
                        (NNS:[1047..1054] mutants))
                    (VP (VBG:[1055..1064] occurring)
                      (PP-LOC (IN:[1065..1067] in)
                        (NP (JJ:[1068..1076] cervical)
                            (NN:[1077..1086] carcinoma))))))))))))
    (.:[1086..1087] .)))

;sentence 10 Span:1089..1163
;Thirty-three patients with early-stage cervical carcinoma were identified.
;[1116..1146]:malignancy:"early-stage cervical carcinoma"
(SENT
  (S
    (NP-SBJ-1
      (NP (CD:[1089..1101] Thirty-three) (NNS:[1102..1110] patients))
      (PP (IN:[1111..1115] with)
        (NP
          (NML (JJ:[1116..1121] early) (HYPH:[1121..1122] -)
               (NN:[1122..1127] stage))
          (JJ:[1128..1136] cervical) (NN:[1137..1146] carcinoma))))
    (VP (VBD:[1147..1151] were)
      (VP (VBN:[1152..1162] identified)
        (NP-1 (-NONE-:[1162..1162] *))))
    (.:[1162..1163] .)))

;sentence 11 Span:1164..1211
;DNA  was extracted from archival tumor samples.
;[1197..1210]:malignancy:"tumor samples"
(SENT
  (S
    (NP-SBJ-1 (NN:[1164..1167] DNA))
    (VP (VBD:[1169..1172] was)
      (VP (VBN:[1173..1182] extracted)
        (NP-1 (-NONE-:[1182..1182] *))
        (PP (IN:[1183..1187] from)
          (NP (JJ:[1188..1196] archival)
             (NN:[1197..1202] tumor) (NNS:[1203..1210] samples)))))
    (.:[1210..1211] .)))

;sentence 12 Span:1212..1491
;ras genes were PCR amplified using  flanking primers and hybridized with a
;series of labeled allele-specific  oligonucleotides corresponding to
;wild-type forms of K12,61, N12,13,61, and  H12,61, as well as to all
;combinations of substitution mutations (7 wild-type,  45 mutants).
;[1212..1215]:gene-rna:"ras"
;[1375..1376]:gene-rna:"K"
;[1376..1378]:variation-location:"12"
;[1379..1381]:variation-location:"61"
;[1383..1384]:gene-rna:"N"
;[1384..1386]:variation-location:"12"
;[1387..1389]:variation-location:"13"
;[1390..1392]:variation-location:"61"
;[1399..1400]:gene-rna:"H"
;[1400..1402]:variation-location:"12"
;[1403..1405]:variation-location:"61"
;[1441..1453]:variation-type:"substitution"
;[1454..1463]:variation-event:"mutations"
(SENT
  (S
    (NP-SBJ-1 (NN:[1212..1215] ras) (NNS:[1216..1221] genes))
    (VP (VBD:[1222..1226] were)
      (VP
        (VP (NN:[1227..1230] PCR) (VBN:[1231..1240] amplified)
          (NP-1 (-NONE-:[1240..1240] *))
          (S-MNR
            (NP-SBJ (-NONE-:[1240..1240] *))
            (VP (VBG:[1241..1246] using)
              (NP (VBG:[1248..1256] flanking) (NNS:[1257..1264] primers)))))
        (CC:[1265..1268] and)
        (VP (VBN:[1269..1279] hybridized)
          (NP-1 (-NONE-:[1279..1279] *))
          (PP-CLR (IN:[1280..1284] with)
            (NP
              (NP (DT:[1285..1286] a) (NN:[1287..1293] series))
              (PP (IN:[1294..1296] of)
                (NP
                  (NP (VBN:[1297..1304] labeled)
                    (ADJP (NN:[1305..1311] allele) (HYPH:[1311..1312] -)
                          (JJ:[1312..1320] specific))
                    (NNS:[1322..1338] oligonucleotides))
                  (VP (VBG:[1339..1352] corresponding)
                    (PP-CLR
                      (PP (TO:[1353..1355] to)
                        (NP
                          (NP
                            (NML (JJ:[1356..1360] wild) (HYPH:[1360..1361] -)
                                 (NN:[1361..1365] type))
                            (NNS:[1366..1371] forms))
                          (PP (IN:[1372..1374] of)
                            (NP
                              (NP (NN:[1375..1376] K) (CD:[1376..1378] 12)
                                  (,:[1378..1379] ,) (CD:[1379..1381] 61))
                              (,:[1381..1382] ,)
                              (NP (NN:[1383..1384] N) (CD:[1384..1386] 12)
                                  (,:[1386..1387] ,) (CD:[1387..1389] 13)
                                  (,:[1389..1390] ,) (CD:[1390..1392] 61))
                              (,:[1392..1393] ,) (CC:[1394..1397] and)
                              (NP (NN:[1399..1400] H) (CD:[1400..1402] 12)
                                  (,:[1402..1403] ,) (CD:[1403..1405] 61))))))
                      (,:[1405..1406] ,)
                      (CONJP (RB:[1407..1409] as) (RB:[1410..1414] well)
                             (IN:[1415..1417] as))
                      (PP (TO:[1418..1420] to)
                        (NP
                          (NP (DT:[1421..1424] all)
                              (NNS:[1425..1437] combinations))
                          (PP (IN:[1438..1440] of)
                            (NP (NN:[1441..1453] substitution)
                                (NNS:[1454..1463] mutations)))
                          (PRN (-LRB-:[1464..1465] -LRB-)
                            (NP
                              (NP (CD:[1465..1466] 7)
                                (NML (JJ:[1467..1471] wild)
                                     (HYPH:[1471..1472] -)
                                     (NN:[1472..1476] type)))
                              (,:[1476..1477] ,)
                              (NP (CD:[1479..1481] 45)
                                (NML (NNS:[1482..1489] mutants))))
                            (-RRB-:[1489..1490] -RRB-)))))))))))))
    (.:[1490..1491] .)))

;sentence 13 Span:1492..1500
;RESULTS:
(SENT
  (NP (NNS:[1492..1499] RESULTS) (::[1499..1500] :)))

;sentence 14 Span:1501..1553
;ras mutations were identified in 24.2% of specimens.
;[1501..1504]:gene-rna:"ras"
;[1505..1514]:variation-event:"mutations"
(SENT
  (S
    (NP-SBJ-1 (NN:[1501..1504] ras) (NNS:[1505..1514] mutations))
    (VP (VBD:[1515..1519] were)
      (VP (VBN:[1520..1530] identified)
        (NP-1 (-NONE-:[1530..1530] *))
        (PP (IN:[1531..1533] in)
          (NP
            (NP (CD:[1534..1538] 24.2) (NN:[1538..1539] %))
            (PP (IN:[1540..1542] of)
              (NP (NNS:[1543..1552] specimens)))))))
    (.:[1552..1553] .)))

;sentence 15 Span:1554..1622
;The  detected mutations in H, K, and N-ras all occurred at codon 61.
;[1568..1577]:variation-event:"mutations"
;[1581..1582]...[1592..1596]:gene-rna:"H"..."-ras"
;[1584..1585]...[1592..1596]:gene-rna:"K"..."-ras"
;[1591..1596]:gene-rna:"N-ras"
;[1613..1621]:variation-location:"codon 61"
(SENT
  (S
    (NP-SBJ
      (NP
        (NP (DT:[1554..1557] The) (VBN:[1559..1567] detected)
            (NNS:[1568..1577] mutations))
        (PP-LOC (IN:[1578..1580] in)
          (NP
            (NP (NN:[1581..1582] H)
              (NML-1 (-NONE-:[1582..1582] *P*)))
            (,:[1582..1583] ,)
            (NP (NN:[1584..1585] K)
              (NML-1 (-NONE-:[1585..1585] *P*)))
            (,:[1585..1586] ,) (CC:[1587..1590] and)
            (NP (NN:[1591..1592] N) (HYPH:[1592..1593] -)
              (NML-1 (NN:[1593..1596] ras))))))
      (NP (DT:[1597..1600] all)))
    (VP (VBD:[1601..1609] occurred)
      (PP-LOC (IN:[1610..1612] at)
        (NP (NN:[1613..1618] codon) (CD:[1619..1621] 61))))
    (.:[1621..1622] .)))

;sentence 16 Span:1623..1767
;This was not the  result of PCR or hybridization artifact in that mutations
;were detected in  position 12 and 13 in appropriate control samples.
;[1689..1698]:variation-event:"mutations"
;[1726..1728]:variation-location:"12"
;[1733..1735]:variation-location:"13"
(SENT
  (S
    (NP-SBJ (DT:[1623..1627] This))
    (VP (VBD:[1628..1631] was) (RB:[1632..1635] not)
      (NP-PRD
        (NP (DT:[1636..1639] the) (NN:[1641..1647] result))
        (PP (IN:[1648..1650] of)
          (NP
            (NP (NN:[1651..1654] PCR))
            (CC:[1655..1657] or)
            (NP (NN:[1658..1671] hybridization) (NN:[1672..1680] artifact)))))
      (SBAR-ADV (IN:[1681..1683] in) (IN:[1684..1688] that)
        (S
          (NP-SBJ-1 (NNS:[1689..1698] mutations))
          (VP (VBD:[1699..1703] were)
            (VP (VBN:[1704..1712] detected)
              (NP-1 (-NONE-:[1712..1712] *))
              (PP-LOC (IN:[1713..1715] in)
                (NP
                  (NP
                    (NML-2 (NN:[1717..1725] position))
                    (CD:[1726..1728] 12))
                  (CC:[1729..1732] and)
                  (NP
                    (NML-2 (-NONE-:[1732..1732] *P*))
                    (CD:[1733..1735] 13))))
              (PP-LOC (IN:[1736..1738] in)
                (NP (JJ:[1739..1750] appropriate) (NN:[1751..1758] control)
                    (NNS:[1759..1766] samples))))))))
    (.:[1766..1767] .)))

;sentence 17 Span:1768..1780
;CONCLUSIONS:
(SENT
  (NP (NNS:[1768..1779] CONCLUSIONS) (::[1779..1780] :)))

;sentence 18 Span:1781..1875
;Mutant ras has  been shown to convert HPV immortalized keratinocytes to the
;tumorigenic state.
;[1788..1791]:gene-rna:"ras"
(SENT
  (S
    (NP-SBJ-1 (JJ:[1781..1787] Mutant) (NN:[1788..1791] ras))
    (VP (VBZ:[1792..1795] has)
      (VP (VBN:[1797..1801] been)
        (VP (VBN:[1802..1807] shown)
          (S
            (NP-SBJ-1 (-NONE-:[1807..1807] *))
            (VP (TO:[1808..1810] to)
              (VP (VB:[1811..1818] convert)
                (NP
                  (ADJP (NN:[1819..1822] HPV) (VBN:[1823..1835] immortalized))
                  (NNS:[1836..1849] keratinocytes))
                (PP-CLR (TO:[1850..1852] to)
                  (NP (DT:[1853..1856] the) (JJ:[1857..1868] tumorigenic)
                      (NN:[1869..1874] state)))))))))
    (.:[1874..1875] .)))

;sentence 19 Span:1877..1997
;Our results indicate that a significant percentage (24.2%) of these
;early-stage  cervical cancers contain activated ras.
;[1945..1974]:malignancy:"early-stage  cervical cancers"
;[1993..1996]:gene-rna:"ras"
(SENT
  (S
    (NP-SBJ (PRP$:[1877..1880] Our) (NNS:[1881..1888] results))
    (VP (VBP:[1889..1897] indicate)
      (SBAR (IN:[1898..1902] that)
        (S
          (NP-SBJ
            (NP (DT:[1903..1904] a) (JJ:[1905..1916] significant)
                (NN:[1917..1927] percentage)
              (PRN (-LRB-:[1928..1929] -LRB-)
                (NP (CD:[1929..1933] 24.2) (NN:[1933..1934] %))
                (-RRB-:[1934..1935] -RRB-)))
            (PP (IN:[1936..1938] of)
              (NP (DT:[1939..1944] these)
                
                (NML (JJ:[1945..1950] early) (HYPH:[1950..1951] -)
                     (NN:[1951..1956] stage))
                (JJ:[1958..1966] cervical) (NNS:[1967..1974] cancers))))
          (VP (VBP:[1975..1982] contain)
            (NP (VBN:[1983..1992] activated) (NN:[1993..1996] ras))))))
    (.:[1996..1997] .)))

;sentence 20 Span:1998..2152
;Additional studies will be needed to  evaluate whether codon 61 represents a
;characteristic "hot-spot" of ras mutation  in a subset of cervical
;carcinoma.
;[2053..2061]:variation-location:"codon 61"
;[2104..2107]:gene-rna:"ras"
;[2133..2151]:malignancy:"cervical carcinoma"
(SENT
  (S
    (NP-SBJ-1 (JJ:[1998..2008] Additional) (NNS:[2009..2016] studies))
    (VP (MD:[2017..2021] will)
      (VP (VB:[2022..2024] be)
        (VP (VBN:[2025..2031] needed)
          (NP-1 (-NONE-:[2031..2031] *))
          (S-PRP
            (NP-SBJ (-NONE-:[2031..2031] *))
            (VP (TO:[2032..2034] to)
              (VP (VB:[2036..2044] evaluate)
                (SBAR-NOM (IN:[2045..2052] whether)
                  (S
                    (NP-SBJ (NN:[2053..2058] codon) (CD:[2059..2061] 61))
                    (VP (VBZ:[2062..2072] represents)
                      (NP
                        (NP (DT:[2073..2074] a) (JJ:[2075..2089] characteristic)
                            (``:[2090..2091] ") (JJ:[2091..2094] hot)
                            (HYPH:[2094..2095] -) (NN:[2095..2099] spot)
                            ('':[2099..2100] "))
                        (PP (IN:[2101..2103] of)
                          (NP (NN:[2104..2107] ras) (NN:[2108..2116] mutation)))
                        (PP (IN:[2118..2120] in)
                          (NP
                            (NP (DT:[2121..2122] a) (NN:[2123..2129] subset))
                            (PP (IN:[2130..2132] of)
                              (NP (JJ:[2133..2141] cervical)
                                  (NN:[2142..2151] carcinoma)))))))))))))))
    (.:[2151..2152] .)))

;section 21 Span:2156..2200
;PMID: 9159349 [PubMed - indexed for MEDLINE]
(SEC
  (FRAG (NNP:[2156..2160] PMID) (::[2160..2161] :) (CD:[2162..2169] 9159349)
        (NN:[2170..2171] -LSB-) (NNP:[2171..2177] PubMed) (::[2178..2179] -)
        (NN:[2180..2187] indexed) (IN:[2188..2191] for)
        (NNP:[2192..2200] MEDLINE-RSB-)))
